Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden administration for Medicare coverage of weight-loss drugs such as Novo Nordisk's Wegovy.

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade barriers.

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed Medicare to cover blockbuster weight loss drugs.

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis found.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that inhibits the body's production of a dangerous type of "bad" cholesterol."

India took a much-needed step in the fight against obesity and diabetes with the introduction of Mounjaro (tirzepatide), a drug developed by American pharmaceutical giant Eli Lilly and Co. Approved by the Central Drugs Standard Control Organisation (CDSCO),